NM_004360.5(CDH1):c.755T>G (p.Val252Gly) AND Hereditary diffuse gastric adenocarcinoma

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Apr 21, 2020
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001342367.7

Allele description [Variation Report for NM_004360.5(CDH1):c.755T>G (p.Val252Gly)]

NM_004360.5(CDH1):c.755T>G (p.Val252Gly)

Gene:

CDH1:cadherin 1 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

16q22.1

Genomic location:

Preferred name:

NM_004360.5(CDH1):c.755T>G (p.Val252Gly)

HGVS:

NC_000016.10:g.68810264T>G
NG_008021.1:g.77973T>G
NM_001317184.2:c.755T>G
NM_001317185.2:c.-861T>G
NM_001317186.2:c.-1065T>G
NM_004360.5:c.755T>GMANE SELECT
NP_001304113.1:p.Val252Gly
NP_004351.1:p.Val252Gly
LRG_301t1:c.755T>G
LRG_301:g.77973T>G
NC_000016.9:g.68844167T>G
NM_004360.3:c.755T>G

Protein change:

V252G

Links:

dbSNP: rs1960782710

NCBI 1000 Genomes Browser:

rs1960782710

Molecular consequence:

NM_001317185.2:c.-861T>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001317186.2:c.-1065T>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001317184.2:c.755T>G - missense variant - [Sequence Ontology: SO:0001583]
NM_004360.5:c.755T>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary diffuse gastric adenocarcinoma (HDGC)
Synonyms:: Hereditary diffuse gastric cancer
Identifiers:: MONDO: MONDO:0007648; MedGen: C1708349; Orphanet: 26106; OMIM: 137215

Recent activity

Clear Turn Off Turn On

Homo sapiens carbonyl reductase 1 (CBR1), transcript variant 2, mRNA
Homo sapiens carbonyl reductase 1 (CBR1), transcript variant 2, mRNA
gi|1675079549|ref|NM_001286789.2|

Nucleotide
Good Practice Guidance – Interim Process Statement
Good Practice Guidance – Interim Process Statement
"895542-94-6"[CompleteSynonym] (1)
PubChem Compound
TSA: Onchocerca flexuosa mRNA sequence
TSA: Onchocerca flexuosa mRNA sequence
gi|328557411|gnl|gpid:65265|isotig2 OnflCeel|gb|JI460617.1|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV001536295	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Apr 21, 2020)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV001536295

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Apr 21, 2020)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001536295.4

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CDH1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with glycine at codon 252 of the CDH1 protein (p.Val252Gly). The valine residue is highly conserved and there is a moderate physicochemical difference between valine and glycine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine